CD24 polymorphisms in breast cancer: impact on prognosis and risk

Overexpression of CD24 has a negative impact on breast cancer prognosis. We have recently reported that the CD24 codon 57 Val/Val genotype (rs52812045) is associated with pathologic complete response after neoadjuvant chemotherapy for primary breast cancer and correlates with intratumoral lymphocyte infiltrates. This study was performed to investigate the influence of CD24 polymorphisms on breast cancer prognosis and risk. A total of 2,514 patients and 4,858 controls recruited as part of the MARIE study, a population-based case–control study, were genotyped for two CD24 polymorphisms (rs52812045, rs3838646) using TaqMan custom genotyping assays. Associations with overall and breast cancer-specific survival were assessed using uni- and multivariable Cox regression models stratified by age at diagnosis and adjusted for prognostic factors. Conditional logistic regression analysis adjusted for major risk factors was used to estimate multivariable odds ratios for risk of putative allele carriers compared to wildtype carriers. CD24 Ala/Val was significantly associated with breast cancer prognosis [Val/Val hazard ratio (HR)adjusted = 1.52; 95 % confidence interval (CI): 1.00–2.30, p = 0.05 and HRadjusted = 1.83; 95 % CI: 1.10–3.05, p = 0.018 for all-cause and breast cancer-specific mortality, respectively). The association was significant only in patients with a BMI <25 and in those who received adjuvant chemotherapy. None of the CD24 alleles was associated with breast cancer risk. These results provide further evidence of the CD24 Val/Val genotype influencing outcome in primary breast cancer. Together with previous data of CD24 overexpression as a poor prognostic marker, the findings underline the biological importance of CD24 for breast cancer.

[1]  P. Altevogt,et al.  CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. , 1997, Blood.

[2]  Klaus Ley,et al.  CD24 mediates rolling of breast carcinoma cells on P‐selectin , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  P. Altevogt,et al.  CD24 is a marker for human breast carcinoma. , 1999, Cancer letters.

[4]  C. Pilarsky,et al.  CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. , 2002, The American journal of pathology.

[5]  I. Petersen,et al.  CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients , 2003, British Journal of Cancer.

[6]  Yang Liu,et al.  CD24 is a genetic modifier for risk and progression of multiple sclerosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[7]  C. Pilarsky,et al.  CD24 expression is a new prognostic marker in breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  Yan Liu,et al.  CD24 Controls Expansion and Persistence of Autoreactive T Cells in the Central Nervous System during Experimental Autoimmune Encephalomyelitis , 2004, The Journal of experimental medicine.

[9]  C. Pilarsky,et al.  Expression of CD24 in Adenocarcinomas of the Pancreas Correlates with Higher Tumor Grades , 2004, Pancreatology.

[10]  S. Loening,et al.  CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer , 2004, The Prostate.

[11]  W. Weichert,et al.  Cytoplasmic CD24 Expression in Colorectal Cancer Independently Correlates with Shortened Patient Survival , 2005, Clinical Cancer Research.

[12]  J. Sleeman,et al.  CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. , 2005, Cancer research.

[13]  G. Kristiansen,et al.  Prognostic value of immunohistochemical estimation of CD24 and Ki67 expression in cisplatin and paclitaxel treated ovarian carcinoma patients. , 2005, Polish journal of pathology : official journal of the Polish Society of Pathologists.

[14]  Peter Altevogt,et al.  CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells , 2006, Journal of Cell Science.

[15]  J. Ruiz‐Martinez,et al.  CD24 V/V is an allele associated with the risk of developing multiple sclerosis in the Spanish population , 2006, Multiple sclerosis.

[16]  P. Rehak,et al.  CD24 expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression , 2006, Virchows Archiv.

[17]  Yang Liu,et al.  CD24: a genetic checkpoint in T cell homeostasis and autoimmune diseases. , 2007, Trends in immunology.

[18]  Sally Hunsberger,et al.  Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Javier Martín,et al.  Association of a CD24 gene polymorphism with susceptibility to systemic lupus erythematosus. , 2007, Arthritis and rheumatism.

[20]  L. Zitvogel,et al.  The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy , 2007, Immunological reviews.

[21]  W. Willett,et al.  A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer , 2007, Nature Genetics.

[22]  Laurence Zitvogel,et al.  Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.

[23]  Yang Liu,et al.  A Dinucleotide Deletion in CD24 Confers Protection against Autoimmune Diseases , 2007, PLoS genetics.

[24]  Yang Liu,et al.  Autoreactive T Cells Escape Clonal Deletion in the Thymus by a CD24-Dependent Pathway1 , 2008, The Journal of Immunology.

[25]  Peter Altevogt,et al.  Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA. , 2008, Cancer research.

[26]  B. Melichar,et al.  Tumor-Infiltrating Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Patients with Breast Carcinoma , 2008, Cancer investigation.

[27]  C. Harding,et al.  Antigen processing and CD24 expression determine antigen presentation by splenic CD4+ and CD8+ dendritic cells , 2008, Immunology.

[28]  Javier Martín,et al.  Association of CD24 gene polymorphisms with susceptibility to biopsy-proven giant cell arteritis. , 2008, The Journal of rheumatology.

[29]  K. Hess,et al.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  L. Zitvogel,et al.  The anticancer immune response: indispensable for therapeutic success? , 2008, The Journal of clinical investigation.

[31]  J. Chang-Claude,et al.  Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy , 2008, International journal of cancer.

[32]  Masoud Etemadifar,et al.  CD24 gene polymorphism is associated with the disease progression and susceptibility to multiple sclerosis in the Iranian population , 2009, Psychiatry Research.

[33]  Yang Liu,et al.  CD24 polymorphisms affect risk and progression of chronic hepatitis B virus infection , 2009, Hepatology.

[34]  S. Qiu,et al.  CD24 Is a Novel Predictor for Poor Prognosis of Hepatocellular Carcinoma after Surgery , 2009, Clinical Cancer Research.

[35]  J. Pignon,et al.  Immunogenic death of colon cancer cells treated with oxaliplatin , 2010, Oncogene.

[36]  Carsten Denkert,et al.  Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  D. Yin,et al.  CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes , 2011, Breast Cancer Research and Treatment.

[38]  T. Schlange,et al.  CD24 promotes tumor cell invasion by suppressing tissue factor pathway inhibitor-2 (TFPI-2) in a c-Src-dependent fashion , 2011, Clinical & Experimental Metastasis.

[39]  S. Tangye,et al.  Inflammatory Mechanisms in Obesity , 2013 .

[40]  A. Schneeweiss,et al.  CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer , 2012, Breast Cancer Research and Treatment.

[41]  J. Chang-Claude,et al.  Estimated enterolignans, lignan-rich foods, and fibre in relation to survival after postmenopausal breast cancer , 2011, British Journal of Cancer.

[42]  M. Bani,et al.  Breast Cancer Risk - Genes, Environment and Clinics. , 2011, Geburtshilfe und Frauenheilkunde.

[43]  P. Watson,et al.  Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer , 2011, Breast Cancer Research.

[44]  I. Ellis,et al.  The prognostic significance of B lymphocytes in invasive carcinoma of the breast , 2012, Breast Cancer Research and Treatment.

[45]  Patrick Neven,et al.  Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. , 2011, Human molecular genetics.

[46]  Jaana M. Hartikainen,et al.  The role of genetic breast cancer susceptibility variants as prognostic factors. , 2012, Human molecular genetics.

[47]  K. Hemminki,et al.  Effect of autoimmune diseases on risk and survival in female cancers. , 2012, Gynecologic oncology.

[48]  Daniel J. Park,et al.  19p13.1 is a triple-negative-specific breast cancer susceptibility locus. , 2012, Cancer research.

[49]  F. Gu,et al.  Peritumoral FOXP3+ regulatory T cell is sensitive to chemotherapy while intratumoral FOXP3+ regulatory T cell is prognostic predictor of breast cancer patients , 2012, Breast Cancer Research and Treatment.

[50]  M. Yamaguchi,et al.  Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer. , 2012, Human pathology.

[51]  T. Schlange,et al.  CD24 controls Src/STAT3 activity in human tumors , 2012, Cellular and Molecular Life Sciences.

[52]  H. Sell,et al.  Adaptive immunity in obesity and insulin resistance , 2012, Nature Reviews Endocrinology.

[53]  C. Lawton,et al.  Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer , 2012 .